340 likes | 381 Views
This program discusses the use of biomarkers in multiple sclerosis (MS) and their role in guiding treatment decisions. It covers topics such as the 2017 McDonald Criteria, CSF oligoclonal bands as prognostic markers, the use of MRI as a biomarker, and the practical advantages of measuring neurofilaments in serum. Real-life evidence and case studies are presented to demonstrate the influence of biomarkers on treatment decision-making.
E N D
Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
MRI as a Biomarker to Guide Treatment Decision: Clinician's Assessment of the Case
Low or Continuously High NfL Levels and Potential Treatment Decision
Real-Life Evidence With NfL in CSF: Influence in Treatment Decision-Making
High NfL Levels and Decision to Initiate Therapy: Czech Republic
High NfL Levels and Decision to Initiate Therapy: Switzerland
High NfL Levels and Decision to Initiate Therapy: United Kingdom
Serum NfL Levels as a Predictor of Disease Worsening and Brain and Spinal Cord Atrophy
Brain Atrophy: Focal Cord and Brain Lesions in RRMS and SPMS
Baseline Tests for Patients Starting on Anti-CD20 Therapy: Infection Screening